Table IV.
Analysis of the distribution of the XRCC1 and XPD triple-location genotypes in hepatocellular carcinoma (HCC) group and control group stratified according to tobacco smoking status.
| Genotype | Tobacco smoking (+)
|
Tobacco smoking (−)
|
||||||
|---|---|---|---|---|---|---|---|---|
| HCC group (n) | Control group (n) | OR (95% CI) | P-values | HCC group (n) | Control group (n) | OR (95% CI) | P-values | |
| XRCC1 Arg194Trp | ||||||||
| CC | 78 | 81 | 1.00 | 0.83 | 41 | 47 | 1.00 | 0.28 |
| CT + TT | 90 | 88 | 1.05 (0.73–1.52) | 43 | 34 | 1.48 (0.87–2.52) | ||
| XRCC1 Arg280His | ||||||||
| GG | 125 | 136 | 1.00 | 0.19 | 68 | 70 | 1.00 | 0.40 |
| GA + AA | 43 | 33 | 1.38 (0.88–2.18) | 16 | 11 | 1.48 (0.72–3.04) | ||
| XPD Asp312Asn | ||||||||
| GG | 120 | 139 | 1.00 | 0.02 | 72 | 68 | 1.00 | 0.83 |
| GA + AA | 48 | 30 | 1.87 (1.18–2.96) | 12 | 13 | 0.89 (0.42–1.84) | ||
OR values were adjusted by gender, age, alcohol consumption, HBV antigen and family history.